| The investigational use of tPA for stroke. | |
| | |
MedLine Citation:
|
PMID: 3142318 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Stroke therapy trials have historically allowed for late patient entry (ie, within 24 to 48 hours from stroke onset) despite evidence suggesting the importance of early intervention. Experimental studies of cerebral infarction suggest treatment may be most effective when begun within three hours and may be only marginally effective when begun after 12 hours. Lysis of an acute intra-arterial thrombus in the setting of thrombolytic therapy is also time dependent. We describe an ongoing dose-escalation study of tissue plasminogen activator (tPA) as ultra-early therapy for cerebral infarction. The protocol requires that hemorrhage be ruled out by computed tomography scan of the brain prior to tPA infusion, and the infusion must begin within 90 minutes of symptom onset. The two primary goals of the study are to assess safety and potential efficacy. Preliminary results from the study and the future of ultra-early stroke intervention are discussed. |
| | |
Authors:
|
T Brott; E C Haley; D E Levy; W G Barsan; R L Reed; C P Olinger; J R Marler |
Related Documents
:
|
11462778 - The failure of neuronal protective agents versus the success of thrombolysis in the tre... 1556998 - Ischemic stroke in patients under age 45. 15781528 - Perioperative fluid management and clinical outcomes in adults. 9222178 - Time course of the apparent diffusion coefficient (adc) abnormality in human stroke. 949718 - Alternation in mitral valve and septal movements in a patient with pulsus alternans. 19762308 - Complete atrioventricular block with bradycardia after craniotomy. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Annals of emergency medicine Volume: 17 ISSN: 0196-0644 ISO Abbreviation: Ann Emerg Med Publication Date: 1988 Nov |
Date Detail:
|
Created Date: 1988-12-12 Completed Date: 1988-12-12 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 8002646 Medline TA: Ann Emerg Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1202-5 Citation Subset: AIM; IM |
Affiliation:
|
University of Cincinnati Medical Center, Department of Neurology, Ohio 45267. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cerebral Hemorrhage
/
chemically induced Cerebral Infarction / drug therapy, physiopathology Cerebrovascular Disorders / drug therapy* Humans Tissue Plasminogen Activator / adverse effects, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
N01-NS-3-2324/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Investigational use of tPA in acute stroke.
Next Document: Thrombolytic therapy in the treatment of peripheral arterial occlusions.